Company Overview - Scinai Immunotherapeutics Ltd. is a biopharmaceutical company listed on Nasdaq under the ticker SCNI, focusing on inflammation and immunology (I&I) biological therapeutic products and providing CDMO services for early-stage biotech drug development [1][2] Business Units - The company operates two complementary business units: one dedicated to the in-house development of innovative nanosized VHH antibodies (nanoAbs) targeting diseases with significant unmet medical needs, and the other offering a boutique CDMO service that includes biological drug development, analytical methods development, clinical cGMP manufacturing, and trial design and execution [1] Recent Developments - Scinai has released a year-end video showcasing its key accomplishments and achievements for 2024, highlighting its progress and future plans [1] Target Audience - The company is engaging with institutional and private investors, potential pharmaceutical partners in the inflammation and immunology field, and prospective clients for its comprehensive biologics CDMO services [3]
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences